|
|
Haorui supplies
Amifostine API
(Active Pharmaceutical Ingredient) to pharmaceutical
industry.
Haorui's
Amifostine API
is produced by
FDA approved cGMP facilities,
we supply Amifostine API from small
R&D to large commercial quantity. For product and supply
details please contact us. |
|
Amifostine
Patents 4 |
|
Amifostine Clinical Trials 1
Amifostine Clinical Trials 2 |
|
Amifostine Patents 1
Amifostine Patents 2
Amifostine Patents 3 |
|
Amifostine Patents 4
Amifostine Patents 5 |
| 151 |
6,858,638 |
Substituted indazoles,
compositions containing them, method of production
and use |
| 152 |
6,858,608 |
Chemical derivatives
and their application as antitelomerase agents
|
| 153 |
6,855,365 |
Recombinant bacterial
phytases and uses thereof
|
| 154 |
6,841,545 |
Stable amorphous
amifostine compositions and methods for the
preparation of same |
| 155 |
6,828,456 |
2-amino-2-alkyl-3
hexenoic and hexynoic acid derivatives useful as
nitric oxide synthase inhibitors |
| 156 |
6,828,440 |
Spiroindene and
spiroindane compounds |
| 157 |
6,822,102 |
Dihydrobenzopyrans,
dihydrobenzothiopyrans, and tetrahydroquinolines for
the treatment of COX-2 mediated disorders |
| 158 |
6,822,097 |
Compounds and methods
of uses |
| 159 |
6,811,967 |
Method for assaying
non-spermine/spermidine activity of spermidine/spermine
N1-acetyltransferase (SSAT)
|
| 160 |
6,806,288 |
Substituted
benzopyran derivatives for the treatment
|
| 161 |
6,787,668 |
2-amino-4,5 heptenoic
acid derivatives useful as nitric oxide synthase
inhibitors |
| 162 |
6,774,116 |
Prodrugs via
acylation with cinnamate |
| 163 |
6,773,669 |
Flow electroporation
chamber and method |
| 164 |
6,767,926 |
Method for protecting
normal cells from cytotoxicity of chemotherapeutic
agents |
| 165 |
6,756,406 |
2-amino-2-alkyl-4
hexenoic and hexynoic acid derivatives useful as
nitric oxide synthase inhibitors |
| 166 |
6,753,323 |
Topical
administration of amifostine and related compounds
|
| 167 |
6,740,641 |
Sugar derivatives of
hydromorphone, dihydromorphine and dihydromorphine,
compositions thereof and uses for treating or
preventing pain |
| 168 |
6,727,238 |
Sulfonylbenzene
compounds as anti-inflammatory/analgesic agents
|
| 169 |
6,720,014 |
Phytase-containing
foodstuffs and methods of making and using them
|
| 170 |
6,720,001 |
Emulsion compositions
for polyfunctional active ingredients |
| 171 |
6,713,081 |
Ocular therapeutic
agent delivery devices and methods for making and
using such devices |
| 172 |
6,709,858 |
Hyperthermic
inducible expression vectors for gene therapy and
methods of use thereof |
| 173 |
6,680,047 |
Diagnostic/therapeutic agents |
| 174 |
6,673,785 |
Use of hepoxilins or
hepoxilin analogs as antidiabetics, antiinflammatory
agents |
| 175 |
6,656,973 |
(E)-4-carboxystyrl-4-chlorobenzyl sulfone and
pharmaceutical compositions thereof |
| 176 |
6,649,636 |
Heteroaryl phenyl
pyrazole compounds as anti-inflammatory/analgesic
agents |
| 177 |
6,645,990 |
Thiazolyl urea
compounds and methods of uses
|
| 178 |
6,645,964 |
Chemical derivatives
and their application as antitelomerase agent |
| 179 |
6,635,653 |
Spiropyrazole
compounds |
| 180 |
6,613,753 |
Restore
cancer-suppressing functions to neoplastic cells
through DNA hypomethylation |
| 181 |
6,608,095 |
Sulfonylbenzene
compounds as anti-inflammatory/analgesic agents
|
| 182 |
6,608,070 |
2,3-substituted
indole compounds as anti-inflammatory and analgesic
agents |
| 183 |
6,603,008 |
Sulfamoylheleroaryl
pyrazole compounds as anti-inflammatory/analgesic
agents |
| 184 |
6,602,902 |
Dha-pharmaceutical
agent conjugates to improve tissue selectivity
|
| 185 |
6,589,941 |
Utilization of 5'
substituted nucleosides for resistance formation in
cytoclastic treatment, and drug containing these
nucleosides, polymers, methods of use and
compositions |
| 186 |
6,586,476 |
Methods for the
treatment of nephro-disorders using aminothiol
compounds |
| 187 |
6,586,474 |
Amidino compounds
useful as nitric oxide synthase inhibitors |
| 188 |
6,586,471 |
Halogenated
2-amino-3, 4 heptenoic acid derivatives useful as
nitric oxide synthase inhibitors |
| 189 |
6,576,636 |
Method of treating a
liver disorder with fatty acid-antiviral agent
conjugates |
| 190 |
6,573,253 |
Methods for the
administration of amifostine and related compounds
|
| 191 |
6,573,063 |
Methods and systems
for assessing biological materials using optical and
spectroscopic detection techniques |
| 192 |
6,572,884 |
Parenteral Cisplatin
emulsion |
| 193 |
6,569,463 |
Solid carriers for
improved delivery of hydrophobic active ingredients
in pharmaceutical compositions
|
| 194 |
6,569,432 |
Prostate-specific
membrane antigen and uses thereof
|
| 195 |
6,566,560 |
Resorcinolic
compounds |
| 196 |
6,565,895 |
Bismuth compounds for
the treatment and prevention of mucositis |
| 197 |
6,552,059 |
Pharmaceutical
composition for and method of treating leukemia
|
| 198 |
6,545,170 |
2-amino-5, 6
heptenoic acid derivatives useful as nitric oxide
synthase inhibitors |
| 199 |
6,541,468 |
Indolocarbazole
derivatives useful for the treatment of
neurodegenerative diseases and cancer |
| 200 |
6,534,089 |
Uniform drug delivery
therapy |
|
|
